Ozmosi | Tipelukast Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Tipelukast

Alternative Names: tipelukast, mn-001
Clinical Status: Active
Latest Update: 2026-01-06
Latest Update Note: News Article

Product Description

Mechanisms of Action: LT Antagonist, PDE Inhibitor, 5-LOX Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: MediciNova
Company Location: Western America
Company CEO: Yuichi Iwaki
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tipelukast

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - MediciNova presented P2 Fatty Liver|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease results on 2024-05-28 for Tipelukast
  • Clinical Outcomes Reported - MediciNova presented P2 Non-alcoholic Fatty Liver Disease results on 2024-05-26 for Tipelukast

Highest Development Phases

Phase 2: Fatty Liver, Alcoholic|Hypertriglyceridemia|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease|Type 2 Diabetes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05464784

 MN-001-NATG-202

P2

Recruiting

Fatty Liver, Alcoholic|Type 2 Diabetes|Hypertriglyceridemia|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease

2025-12-31

50%

2024-11-21

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

Recent News Events

Date

Type

Title

01/06/2026

News Article

 2026 New Year's Greetings from the CEO

12/18/2025

News Article

 MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

12/08/2025

News Article

 MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

12/01/2025

News Article

 Message from the CEO to MediciNova Shareholders

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions